Recombinant Human SNCA, 112aa

• Cat.No.: SNCA-75H
• Product Overview: Recombinant Human α-Synuclein 112 produced inE.Coliis a single,non-glycosylated polypeptide chain having a molecular mass of 11,371 Dalton and 112aa. The Recombinant Human α-Synuclein 112 is purified by proprietary chromatographic techniques.

Specification

• Cat. No.: SNCA-75H
• Description: The α-Synuclein (amino acids 1-140), an acidic neuronal protein of 140 amino acids, is extremely heat-resistant and is natively unfolded with an extended structure primarily composed of random coils. α-synuclein has been suggested to be implicated in the pathogenesis of Parkinson's disease and related neurodegenerative disorders, and more recently, to be an important regulatory component of vesicular transport in neuronal cells. Moreover, recent studies have shown that α-synuclein has chaperone activity and that this activity is lost upon removing its C-terminal acidic tail (amino acids 96-140).
• Source: Escherichia Coli.
• Sequence: MDVFMKGLSK/AKEGVVAAAE/KTKQGVAEAA/GKTKEGVLYV/GSKTKEGVVH/GVATVAEKTK/EQVTNVGGAV/VTGVTAVAQK/TVEGAGSIAA/ATGFVKKDQL/ GKNEEGAPQE/ GILEDMPVDP/DNEAYEMPSE/EGYQDYEPEA.
• Physical Appearance: Sterile filtered clorless solution.
• Purity: Greater than 95.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by reducing and non-reducing SDS-PAGE Coomassie.
• Formulation: The protein (1mg/ml) contains 20mM Tris-HCl buffer (pH 7.5), 0.1M NaCl.
• Storage: Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. Avoid multiple freeze-thaw cycles. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).

Gene Information

• Gene Name: SNCA synuclein, alpha (non A4 component of amyloid precursor) [ Homo sapiens ]
• Synonyms: SNCA; synuclein, alpha (non A4 component of amyloid precursor); PD1; NACP; PARK1; PARK4; MGC110988; Non-A beta component of AD amyloid;Alpha-synuclein;Non-A4 component of amyloid precursor; OTTHUMP00000161559; OTTHUMP00000161561; non A-beta component of AD amyloid
• Gene ID: 6622
• mRNA Refseq: NM_000345
• Protein Refseq: NP_000336
• UniProt ID: P37840
• Chromosome Location: 4q21.3-q22
• MIM: 163890
• Pathway: Alzheimer"s disease; Parkinson"s disease
• Function: Hsp70 protein binding; alpha-tubulin binding; achidonic acid binding; calcium ion binding; caspase inhibitor activity; dynein binding; fatty acid binding; fatty acid binding; ferrous iron binding; histone binding; identical protein binding; kinesin binding; magnesium ion binding; magnesium ion binding; phospholipase inhibitor activity; tau protein binding; transferrin transmembrane transporter activity; zinc ion binding

Reviews

08/31/2020

Its integrity and reliability make it an ideal choice to address the specific objectives of my research.

03/12/2020

Their profound knowledge and expertise will undoubtedly help me overcome any challenges that arise, and their prompt assistance ensures a seamless progression of my research.

10/16/2017

In addition to the exceptional quality of the protein, the manufacturer's support extends beyond the product itself.

Q&As

Can SNCA protein levels in cerebrospinal fluid be used as a diagnostic marker for Parkinson's disease?

Yes, elevated levels of SNCA protein in cerebrospinal fluid can be indicative of Parkinson's disease.

What potential therapeutic strategies target SNCA protein for Parkinson's disease treatment?

Therapies may include reducing SNCA aggregation or preventing its misfolding.

Are there any genetic mutations related to SNCA protein that increase the risk of Parkinson's disease?

Yes, certain mutations in the SNCA gene are associated with familial Parkinson's disease.

How is SNCA protein associated with neurodegenerative diseases?

Aggregates of misfolded SNCA protein are implicated in various neurodegenerative diseases, including Parkinson's disease.

Are there any ongoing clinical trials investigating SNCA-related therapies?

Yes, several clinical trials are exploring treatments targeting SNCA protein in Parkinson's disease.